M A Mignot1, N Taisne1, I Legroux1,2, B Cortet1,2, J Paccou3,4. 1. Department of Rheumatology, Lille University Hospital, Rue Emile Laine, 59037, Lille, France. 2. Lille University - ULCO, PMOI, EA 4490, 59000, Lille, France. 3. Department of Rheumatology, Lille University Hospital, Rue Emile Laine, 59037, Lille, France. julien.paccou@chru-lille.fr. 4. Lille University - ULCO, PMOI, EA 4490, 59000, Lille, France. julien.paccou@chru-lille.fr.
Abstract
A cohort of 183 postmenopausal women, who had either discontinued or continued bisphosphonates (BPs) after first-line therapy, was used to investigate the relationships between "drug holiday" and clinical fracture. The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday." INTRODUCTION: BPs are the most widely used treatment for postmenopausal osteoporosis. The optimal treatment duration, however, remains unclear. The purpose of this study was to evaluate the fracture risk in postmenopausal women with osteoporosis after discontinuing BP treatment (BP "drug holiday"). METHODS: A retrospective analysis was performed at Lille University Hospital (LUH) on postmenopausal women with osteoporosis who had taken a "drug holiday" or continued treatment after first-line BP therapy (3 to 5 years). The occurrence of new clinical fractures during follow-up was also explored. Cox proportional hazards models were used to investigate the relationships between BP "drug holiday" and the occurrence of clinical fractures, while controlling for confounding factors. Survival without new clinical fractures was analyzed using Kaplan-Meier curves and log-rank tests. RESULTS: One hundred eighty-three women (mean age: 61.8 years; SD: 8.7) who had previously undergone BP treatment for 3 to 5 years were enrolled in our study. The patients had received alendronate (n = 81), risedronate (n = 73), zoledronic acid (n = 20), and ibandronate (n = 9). In 166 patients ("drug holiday" group: n = 31; continuous-treatment group: n = 135), follow-up ranged from 6 to 36 months (mean duration: 31.8 months; SD: 8.2). The incidences of new clinical fractures during follow-up were 16.1% (5/31) and 11.9% (16/135). After full adjustment, the hazard ratio of new clinical fractures among "drug holiday" patients was 1.40 (95% CI: 1.12-1.60; p = 0.0095). CONCLUSIONS: After first-line BP therapy in postmenopausal women with osteoporosis, the risk of new clinical fractures was 40% higher in subjects who took a bisphosphonate drug holiday.
A cohort of 183 postmenopausal women, who had either discontinued or continued bisphosphonates (BPs) after first-line therapy, was used to investigate the relationships between "drug holiday" and clinical fracture. The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday." INTRODUCTION:BPs are the most widely used treatment for postmenopausal osteoporosis. The optimal treatment duration, however, remains unclear. The purpose of this study was to evaluate the fracture risk in postmenopausal women with osteoporosis after discontinuing BP treatment (BP "drug holiday"). METHODS: A retrospective analysis was performed at Lille University Hospital (LUH) on postmenopausal women with osteoporosis who had taken a "drug holiday" or continued treatment after first-line BP therapy (3 to 5 years). The occurrence of new clinical fractures during follow-up was also explored. Cox proportional hazards models were used to investigate the relationships between BP "drug holiday" and the occurrence of clinical fractures, while controlling for confounding factors. Survival without new clinical fractures was analyzed using Kaplan-Meier curves and log-rank tests. RESULTS: One hundred eighty-three women (mean age: 61.8 years; SD: 8.7) who had previously undergone BP treatment for 3 to 5 years were enrolled in our study. The patients had received alendronate (n = 81), risedronate (n = 73), zoledronic acid (n = 20), and ibandronate (n = 9). In 166 patients ("drug holiday" group: n = 31; continuous-treatment group: n = 135), follow-up ranged from 6 to 36 months (mean duration: 31.8 months; SD: 8.2). The incidences of new clinical fractures during follow-up were 16.1% (5/31) and 11.9% (16/135). After full adjustment, the hazard ratio of new clinical fractures among "drug holiday" patients was 1.40 (95% CI: 1.12-1.60; p = 0.0095). CONCLUSIONS: After first-line BP therapy in postmenopausal women with osteoporosis, the risk of new clinical fractures was 40% higher in subjects who took a bisphosphonate drug holiday.
Entities:
Keywords:
Bisphosphonates; Clinical fractures; Drug holiday; Postmenopausal osteoporosis
Authors: Maguy Chiha; Lauren E Myers; Caroline A Ball; James M Sinacore; Pauline M Camacho Journal: Endocr Pract Date: 2013 Nov-Dec Impact factor: 3.443
Authors: Douglas C Bauer; Ann Schwartz; Lisa Palermo; Jane Cauley; Marc Hochberg; Art Santora; Steven R Cummings; Dennis M Black Journal: JAMA Intern Med Date: 2014-07 Impact factor: 21.873
Authors: D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud Journal: Lancet Date: 1996-12-07 Impact factor: 79.321
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston Journal: J Bone Miner Res Date: 2015-01 Impact factor: 6.741
Authors: Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell Journal: J Bone Miner Res Date: 2012-02 Impact factor: 6.741
Authors: Felicia Cosman; Jane A Cauley; Richard Eastell; Steven Boonen; Lisa Palermo; Ian R Reid; Steven R Cummings; Dennis M Black Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: E M Dennison; C Cooper; J A Kanis; O Bruyère; S Silverman; E McCloskey; B Abrahamsen; D Prieto-Alhambra; S Ferrari Journal: Osteoporos Int Date: 2019-06-07 Impact factor: 4.507
Authors: Martin Salgueiro; Michael Stribos; Li Fang Zhang; Mark Stevens; Mohamed E Awad; Mohammed Elsalanty Journal: EPMA J Date: 2019-01-24 Impact factor: 6.543